Barclays PLC Purchases 102,046 Shares of Doximity, Inc. (NASDAQ:DOCS)

Barclays PLC lifted its stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 191.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 155,447 shares of the company's stock after acquiring an additional 102,046 shares during the period. Barclays PLC owned approximately 0.08% of Doximity worth $8,299,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in DOCS. Global Retirement Partners LLC raised its stake in shares of Doximity by 468.1% in the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock valued at $29,000 after purchasing an additional 440 shares during the period. UMB Bank n.a. raised its position in Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after buying an additional 235 shares during the last quarter. Larson Financial Group LLC lifted its stake in Doximity by 49.4% in the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after acquiring an additional 250 shares in the last quarter. Optimum Investment Advisors acquired a new position in Doximity during the 4th quarter worth approximately $43,000. Finally, Morse Asset Management Inc bought a new position in shares of Doximity during the 3rd quarter worth approximately $46,000. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on DOCS. Piper Sandler upgraded shares of Doximity from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $31.00 to $78.00 in a report on Friday, February 7th. Needham & Company LLC increased their price objective on shares of Doximity from $65.00 to $82.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Leerink Partners raised Doximity from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Raymond James reissued an "outperform" rating and set a $83.00 price target (up from $65.00) on shares of Doximity in a research report on Friday, February 7th. Finally, Truist Financial decreased their price target on Doximity from $65.00 to $58.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $65.39.

Insiders Place Their Bets

In related news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company's stock, valued at $366,463.20. This represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 37.40% of the company's stock.

Doximity Price Performance

Doximity stock traded up $0.38 during trading hours on Friday, hitting $56.67. The company had a trading volume of 1,364,010 shares, compared to its average volume of 1,992,882. The firm has a 50-day moving average of $60.70 and a 200 day moving average of $56.19. The firm has a market cap of $10.58 billion, a PE ratio of 56.67, a PEG ratio of 4.10 and a beta of 1.41. Doximity, Inc. has a one year low of $22.96 and a one year high of $85.21.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.